Services on Demand
article
Indicators
Cited by SciELO
Related links
Bookmark
Revista chilena de obstetricia y ginecología
version ISSN 0717-7526
Abstract
ZAHRADNIK, Hans Peter; HANJALIC-BECK, Aida and SCHILLING REDLICH, Andrea. Beneficios no anticonceptivos de 0,02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24+4 días. Rev. chil. obstet. ginecol. [online]. 2011, vol.76, n.5, pp. 344-353. ISSN 0717-7526. doi: 10.4067/S0717-75262011000500010.
Objective: To demonstrate the influence on physical and psychological complaints during the first year of intake of the combined oral contraceptive (COC) 0.02 mg ethinylestradiol (EE)/2 mg chlormadinone acetate (CMA), administered in a regimen of 24 days of CMA/EE intake followed by 4 days of placebo intake. Study design: The subjective feelings of non-contraceptive benefits registered in women's diaries of 1,665 subjects participating in a multicentre, uncontrolled, multiadministration, Phase III trial, published elsewhere, were analyzed post-hoc after 13 cycles intake of EE/CMA in a 24 +4 days intake regimen. Results: Emotional complaints were reported less frequently at medication cycle 13 compared with admission and cycle 1. Depressive mood was reduced by 84.5% and 72.2%, irritability by 87.3% and 66.0%; physical complaints were also reduced: headaches by 75.5% and 74.7%, breast discomfort by 77.1% and 66.1%; pre-existing dysmenorrhea by 77.9% and 67.6%. Premature termination due to complaints was only marginal, the bleeding profile was accepted. Conclusions: The low-dose COC, 0.02 mg EE/2 mg CMA, administered in a 24 +4 day regimen, reduces significantly most of the emotional and physical complaints occurring during spontaneous cycles of women, combined with an adequate bleeding profile.
Keywords : Chlormadinone acetate; low-dose ethinylestradiol; 24 +4-day regimen; non-contraceptive benefits; emotional benefits; cycle control.











